| Visualizaciones | |
|---|---|
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study | 75 |
| enero 2024 | febrero 2024 | marzo 2024 | abril 2024 | mayo 2024 | junio 2024 | julio 2024 | |
|---|---|---|---|---|---|---|---|
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study | 11 | 30 | 1 | 7 | 3 | 11 | 12 |
| Visualizaciones | |
|---|---|
| artconlli_a2021_tabernero_josep_encorafenib_plus_cetuximab.pdf | 18 |
| Visualizaciones | |
|---|---|
| Estados Unidos | 34 |
| China | 7 |
| España | 5 |
| Visualizaciones | |
|---|---|
| Menlo Park | 20 |
| Barcelona | 5 |
| Oakland | 5 |
| Shanghai | 5 |
| San Diego | 4 |
| Jackson | 3 |
| Fairfield | 1 |
| Guangzhou | 1 |
| Mountain View | 1 |
| Xingtai | 1 |